Jonas Boström
Jonas Boström
Treeline Biosciences,US
Verified email at
Cited by
Cited by
Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone? Miniperspective
DG Brown, J Bostrom
Journal of medicinal chemistry 59 (10), 4443-4458, 2016
Oxadiazoles in medicinal chemistry
J Boström, A Hogner, A Llinàs, E Wellner, AT Plowright
Journal of medicinal chemistry 55 (5), 1817-1830, 2012
Expanding the medicinal chemistry synthetic toolbox
J Boström, DG Brown, RJ Young, GM Keserü
Nature Reviews Drug Discovery 17 (10), 709-727, 2018
Assessing the performance of OMEGA with respect to retrieving bioactive conformations
J Boström, JR Greenwood, J Gottfries
Journal of Molecular Graphics and Modelling 21 (5), 449-462, 2003
Conformational energy penalties of protein-bound ligands
J Boström, PO Norrby, T Liljefors
Journal of computer-aided molecular design 12, 383-383, 1998
Do structurally similar ligands bind in a similar fashion?
J Boström, A Hogner, S Schmitt
Journal of medicinal chemistry 49 (23), 6716-6725, 2006
Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools
J Boström
Journal of Computer-Aided Molecular Design 15, 1137-1152, 2001
Deep Reinforcement Learning for Multiparameter Optimization in de novo Drug Design
N Ståhl, G Falkman, A Karlsson, G Mathiason, J Bostrom
Journal of chemical information and modeling 59 (7), 3166-3176, 2019
Where do recent small molecule clinical development candidates come from?
DG Brown, J Boström
Journal of medicinal chemistry 61 (21), 9442-9468, 2018
Molecular rift: virtual reality for drug designers
M Norrby, C Grebner, J Eriksson, J Bostrom
Journal of chemical information and modeling 55 (11), 2475-2484, 2015
Computational chemistry-driven decision making in lead generation
V Schnecke, J Boström
Drug discovery today 11 (1-2), 43-50, 2006
Scaffold hopping, synthesis and structure–activity relationships of 5, 6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists
J Boström, K Berggren, T Elebring, PJ Greasley, M Wilstermann
Bioorganic & medicinal chemistry 15 (12), 4077-4084, 2007
Benzothiazepine derivatives
I Starke, MUJ Dahlstrom, D Blomberg, S Alenfalk, P Nordberg, ...
US Patent 7,192,946, 2007
Using matched molecular series as a predictive tool to optimize biological activity
NM O’Boyle, J Boström, RA Sayle, A Gill
Journal of Medicinal Chemistry 57 (6), 2704-2713, 2014
Understanding Our Love Affair with p-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection
DG Brown, MM Gagnon, J Bostrom
Journal of Medicinal Chemistry 58 (5), 2390-2405, 2015
Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
I Starke, MUJ Dahlstrom, MP Nordberg, S Alenfalk, AC Wallberg, ...
US Patent 7,238,684, 2007
Benzothiazepine derivatives
I Starke, S Alenfalk, MP Nordberg, MUJ Dahlstrom, SJ Bostrom, ...
US Patent 8,067,584, 2011
A 3D QSAR study on a set of dopamine D4 receptor antagonists
J Boström, M Böhm, K Gundertofte, G Klebe
Journal of chemical information and computer sciences 43 (3), 1020-1027, 2003
Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid
J Boström, JA Grant, O Fjellström, A Thelin, D Gustafsson
Journal of Medicinal Chemistry 56 (8), 3273-3280, 2013
Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor
P Bach, J Boström, K Brickmann, JJJ Van Giezen, RD Groneberg, ...
European journal of medicinal chemistry 65, 360-375, 2013
The system can't perform the operation now. Try again later.
Articles 1–20